Biomaterial Database

Hormone treatment related bone mineral content changes in Japanese women with endometriosis. 1993

M Fukushima, and M Shindo, and K Sato

Akita University College of Allied Medical Science, Japan.

The effects of a GnRH agonist and danazol on bone mineral content (BMC) in Japanese women with endometriosis were investigated. Nineteen women with laparoscopically confirmed endometriosis were treated with buserelin (900 micrograms/d administered intranasally, 10 cases) or with danazol (400 mg/d p.o., 9 cases) for 6 months. Trabecular BMC of the 3rd lumbar vertebra was measured using quantitative computerized tomography before treatment, at the end of treatment and 6 months after treatment by the same radiologist who was not informed about the drug used. Serum estradiol and the biochemical parameters of bone metabolism were also measured. A significant decrease in BMC (10% on average; maximum 25.4%) was observed at the end of treatment with buserelin (p < 0.01) and this loss was only partially recovered 6 months after treatment. In the danazol group, however, a slight gain in BMC was observed. Buserelin suppressed serum estrogen levels much more than danazol did. Parameters of bone resorption tended to increase in the buserelin group. Because treatment with buserelin, but not with danazol, was always associated with a significant decrease in BMC at L3, repeated usage of buserelin may lead to cumulative bone loss in patients with endometriosis.

UI	MeSH Term	Description	Entries
D007564	Japan	A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo.	Bonin Islands
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D002064	Buserelin	A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.	Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D003613	Danazol	A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	Azol,Cyclomen,Danatrol,Danazant,Danazol-Ratiopharm,Danocrine,Danol,Danoval,Ladogal,Norciden,Panacrine,Danazol Ratiopharm
D004715	Endometriosis	A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	Endometrioma,Endometriomas,Endometrioses
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D015519	Bone Density	The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.	Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral
D016037	Single-Blind Method	A method in which either the observer(s) or the subject(s) is kept ignorant of the group to which the subjects are assigned.	Single-Masked Study,Single-Blind Study,Single-Masked Method,Method, Single-Blind,Method, Single-Masked,Methods, Single-Blind,Methods, Single-Masked,Single Blind Method,Single Blind Study,Single Masked Method,Single Masked Study,Single-Blind Methods,Single-Blind Studies,Single-Masked Methods,Single-Masked Studies,Studies, Single-Blind,Studies, Single-Masked,Study, Single-Blind,Study, Single-Masked

Related Publications

M Fukushima, and M Shindo, and K Sato

Changes in bone mineral content following hormone treatment for endometriosis.

September 1995, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,

M Fukushima, and M Shindo, and K Sato

Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis.

April 2000, The Journal of rheumatology,

M Fukushima, and M Shindo, and K Sato

Bone mineral content in Japanese.

July 1988, Bone and mineral,

M Fukushima, and M Shindo, and K Sato

Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol.

July 1989, Fertility and sterility,

M Fukushima, and M Shindo, and K Sato

Changes in bone mineral content in obese dieting women.

August 1997, Metabolism: clinical and experimental,